Page last updated: 2024-08-23

sisomicin and Pneumonia, Bacterial

sisomicin has been researched along with Pneumonia, Bacterial in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Nambiar, S; Schumann, K; Walinsky, S	1
Connolly, LE; Daikos, GL; Dwyer, JP; Friedland, I; Jubb, AM; Krause, KM; McKinnell, JA; Serio, AW; Smith, A; Talbot, GH	1
Baluya, D; Brown, D; Cirz, R; Drusano, GL; Fikes, S; Kurhanewicz, S; Liu, W; Louie, A; Robbins, N; Rodriquez, J	1

Trials

1 trial(s) available for sisomicin and Pneumonia, Bacterial

Article	Year
Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. The New England journal of medicine, 2019, 02-21, Volume: 380, Issue:8 Topics: Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Colistin; Creatinine; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Healthcare-Associated Pneumonia; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sample Size; Sisomicin	2019

Article

Year

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

The New England journal of medicine, 2019, 02-21, Volume: 380, Issue:8

Topics: Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Colistin; Creatinine; Drug Resistance, Bacterial; Enterobacteriaceae Infections; Healthcare-Associated Pneumonia; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sample Size; Sisomicin

2019

Other Studies

2 other study(ies) available for sisomicin and Pneumonia, Bacterial

Article	Year
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration	2021
Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. The Journal of infectious diseases, 2014, Oct-15, Volume: 210, Issue:8 Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Granulocytes; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sisomicin	2014

Article

Year

FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.

Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4

Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration

2021

Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

The Journal of infectious diseases, 2014, Oct-15, Volume: 210, Issue:8

Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Granulocytes; Mice; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Sisomicin

2014